questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Alcohol oxidoreductases
NAD (+) and NADP (+) dependent Alcohol oxidoreductases
3-Hydroxyacyl-CoA dehydrogenases
Hydroxymethylglutaryl-CoA reductases
Hydroxymethylglutaryl-CoA reductases, NAD-dependent
Hydroxymethylglutaryl-CoA reductases, NAD-dependent : Questions médicales fréquentes
Diagnostic
5
Dyslipidémie
Cholestérol
Enzymes
Tests génétiques
HMG-CoA réductase
Mutations
Hypercholestérolémie
Maladies cardiovasculaires
Symptômes
Activité enzymatique
Tests biochimiques
Évaluation
LDL
Triglycérides
Marqueurs biochimiques
Symptômes
5
Hypercholestérolémie
Symptômes
Douleurs thoraciques
Maladie cardiovasculaire
Essoufflement
Fatigue
Xanthomes
Cholestérol
Signes cutanés
Maladies cardiaques
AVC
Dysfonction
Âge
Symptômes
Population âgée
Prévention
5
Prévention
Alimentation équilibrée
Exercice
Graisses saturées
Sucres ajoutés
Alimentation
Tabagisme
Cholestérol
Risques cardiaques
Activité physique
Cholestérol
Prévention
Bilans de santé
Cholestérol
Détection précoce
Traitements
5
Statines
Hypercholestérolémie
Médicaments
Alimentation
Exercice
Mode de vie
Suppléments
Oméga-3
Phytostérols
Suivi médical
Traitement
Progrès
Efficacité
Maladies cardiovasculaires
Traitements
Complications
5
Complications
Maladies cardiaques
AVC
Athérosclérose
Vaisseaux sanguins
Flux sanguin
Diabète
Complications
Hypercholestérolémie
AVC
Obstruction
Dépôts de cholestérol
Réversibilité
Complications
Gestion
Facteurs de risque
5
Facteurs de risque
Obésité
Tabagisme
Hérédité
Antécédents familiaux
Maladies cardiaques
Stress
Cholestérol
Niveaux élevés
Âge
Facteurs de risque
Dysfonction
Maladies chroniques
Diabète
Hypertension
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent : Questions médicales les plus fréquentes",
"headline": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hydroxymethylglutaryl-CoA reductases, NAD-dependent : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-07",
"dateModified": "2026-02-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases",
"url": "https://questionsmedicales.fr/mesh/D006903",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases",
"code": {
"@type": "MedicalCode",
"code": "D006903",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA Reductases, NAD-Dependent",
"code": {
"@type": "MedicalCode",
"code": "D025781",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Russell A DeBose-Boyd",
"url": "https://questionsmedicales.fr/author/Russell%20A%20DeBose-Boyd",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "George Davey Smith",
"url": "https://questionsmedicales.fr/author/George%20Davey%20Smith",
"affiliation": {
"@type": "Organization",
"name": "Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom."
}
},
{
"@type": "Person",
"name": "Youngah Jo",
"url": "https://questionsmedicales.fr/author/Youngah%20Jo",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "Jonas T Treebak",
"url": "https://questionsmedicales.fr/author/Jonas%20T%20Treebak",
"affiliation": {
"@type": "Organization",
"name": "Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark."
}
},
{
"@type": "Person",
"name": "Mirela Tkalcic Cavuzic",
"url": "https://questionsmedicales.fr/author/Mirela%20Tkalcic%20Cavuzic",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: mtkalc1@lsu.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Hydroxymethylglutaryl-CoA reductase activity is essential for mitochondrial β-oxidation of fatty acids to prevent lethal accumulation of long-chain acylcarnitines in the mouse liver.",
"datePublished": "2024-04-19",
"url": "https://questionsmedicales.fr/article/38641905",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bph.16363"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictive Modeling of HMG-CoA Reductase Inhibitory Activity and Design of New HMG-CoA Reductase Inhibitors.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37546661",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acsomega.3c02567"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mitochondrial 3-hydroxymethylglutaryl-CoA synthase-2 (HMGCS2) deficiency: a rare case with bicytopenia and coagulopathy.",
"datePublished": "2023-11-06",
"url": "https://questionsmedicales.fr/article/37931961",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2023-257011"
}
},
{
"@type": "ScholarlyArticle",
"name": "Developing and enhancing promiscuous activity for NAD(P)H-dependent flavin reductase via elimination of cofactor.",
"datePublished": "2023-08-25",
"url": "https://questionsmedicales.fr/article/37809429",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.heliyon.2023.e19315"
}
},
{
"@type": "ScholarlyArticle",
"name": "HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.",
"datePublished": "2023-07-27",
"url": "https://questionsmedicales.fr/article/37541087",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.bbrc.2023.07.056"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D000429"
},
{
"@type": "ListItem",
"position": 6,
"name": "NAD (+) and NADP (+) dependent Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D064430"
},
{
"@type": "ListItem",
"position": 7,
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"item": "https://questionsmedicales.fr/mesh/D015094"
},
{
"@type": "ListItem",
"position": 8,
"name": "Hydroxymethylglutaryl-CoA reductases",
"item": "https://questionsmedicales.fr/mesh/D006903"
},
{
"@type": "ListItem",
"position": 9,
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"item": "https://questionsmedicales.fr/mesh/D025781"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hydroxymethylglutaryl-CoA reductases, NAD-dependent - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-12",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"description": "Comment diagnostiquer une dysfonction de l'enzyme ?\nQuels tests génétiques sont disponibles ?\nQuels symptômes indiquent un problème enzymatique ?\nComment évaluer l'activité de l'enzyme ?\nQuels marqueurs biochimiques sont pertinents ?",
"url": "https://questionsmedicales.fr/mesh/D025781#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"description": "Quels symptômes sont associés à une hypercholestérolémie ?\nComment se manifeste une maladie cardiovasculaire ?\nY a-t-il des signes cutanés à surveiller ?\nQuels sont les effets à long terme d'une dysfonction ?\nLes symptômes varient-ils selon l'âge ?",
"url": "https://questionsmedicales.fr/mesh/D025781#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"description": "Comment prévenir l'hypercholestérolémie ?\nQuels aliments sont à éviter ?\nLe tabagisme influence-t-il le cholestérol ?\nL'activité physique est-elle cruciale ?\nLes bilans de santé réguliers sont-ils nécessaires ?",
"url": "https://questionsmedicales.fr/mesh/D025781#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"description": "Quels médicaments sont utilisés pour traiter l'hypercholestérolémie ?\nComment les changements de mode de vie aident-ils ?\nY a-t-il des traitements naturels recommandés ?\nQuelle est l'importance du suivi médical ?\nLes traitements sont-ils efficaces à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D025781#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"description": "Quelles sont les complications de l'hypercholestérolémie ?\nComment l'hypercholestérolémie affecte-t-elle les vaisseaux sanguins ?\nY a-t-il un lien avec le diabète ?\nQuels sont les risques d'un AVC ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D025781#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"description": "Quels sont les principaux facteurs de risque ?\nL'hérédité joue-t-elle un rôle ?\nLe stress influence-t-il le cholestérol ?\nL'âge est-il un facteur de risque ?\nLes maladies chroniques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D025781#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de l'enzyme ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de cholestérol et d'enzymes peuvent aider."
}
},
{
"@type": "Question",
"name": "Quels tests génétiques sont disponibles ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests pour identifier des mutations dans le gène HMGCR peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème enzymatique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de cholestérol et des maladies cardiovasculaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité de l'enzyme ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activité enzymatique peut être mesurée par des tests biochimiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biochimiques sont pertinents ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de LDL et de triglycérides sont des marqueurs importants à surveiller."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont associés à une hypercholestérolémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs thoraciques, fatigue et problèmes respiratoires."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une maladie cardiovasculaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des douleurs thoraciques, essoufflement ou fatigue excessive."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés à surveiller ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépôts de cholestérol peuvent apparaître sous forme de xanthomes sur la peau."
}
},
{
"@type": "Question",
"name": "Quels sont les effets à long terme d'une dysfonction ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une dysfonction prolongée peut entraîner des maladies cardiaques et des AVC."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent être plus prononcés chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'hypercholestérolémie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier sont essentiels pour la prévention."
}
},
{
"@type": "Question",
"name": "Quels aliments sont à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé d'éviter les graisses saturées et les sucres ajoutés."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le cholestérol ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut aggraver les niveaux de cholestérol et les risques cardiaques."
}
},
{
"@type": "Question",
"name": "L'activité physique est-elle cruciale ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité physique régulière aide à maintenir un bon niveau de cholestérol."
}
},
{
"@type": "Question",
"name": "Les bilans de santé réguliers sont-ils nécessaires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des bilans réguliers aident à détecter précocement les problèmes de cholestérol."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter l'hypercholestérolémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines sont couramment prescrites pour réduire le cholestérol sanguin."
}
},
{
"@type": "Question",
"name": "Comment les changements de mode de vie aident-ils ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et l'exercice régulier peuvent améliorer les niveaux de cholestérol."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels recommandés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des suppléments comme les oméga-3 et les phytostérols peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du suivi médical ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet d'ajuster le traitement et de surveiller les progrès."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent réduire significativement le risque de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications de l'hypercholestérolémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent les maladies cardiaques, AVC et problèmes vasculaires."
}
},
{
"@type": "Question",
"name": "Comment l'hypercholestérolémie affecte-t-elle les vaisseaux sanguins ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer l'athérosclérose, rétrécissant les vaisseaux et réduisant le flux sanguin."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'hypercholestérolémie augmente le risque de complications chez les diabétiques."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'un AVC ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un AVC peut survenir en raison de l'obstruction des vaisseaux par des dépôts de cholestérol."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le tabagisme, l'inactivité physique et une mauvaise alimentation."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiaques augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il le cholestérol ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des niveaux de cholestérol élevés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de dysfonction enzymatique augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète et l'hypertension augmentent le risque de cholestérol élevé."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/02/2026
Contenu vérifié selon les dernières recommandations médicales
5 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
3 publications dans cette catégorie
Affiliations :
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: mtkalc1@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: gwaldro@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Seattle Structural Genomics Center for Infectious Disease (SSGCID), Seattle, Washington, USA.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
National Institute for Health and Welfare, Helsinki, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research, Oxford Biomedical Research Centre, Oxford University Hospital, Oxford, United Kingdom.
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Homerton College, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Institute of Cardiovascular Science, University College London, London, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Institute of Cardiovascular Science, University College London, London, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Chemistry, Fimlab Laboratories, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technologies, University of Tampere, Tampere, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, University of Turku, Turku, Finland.
Division of Medicine, Turku University Hospital, Turku, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
2 publications dans cette catégorie
Affiliations :
Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.
Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases, NAD-dependent" :
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR), and exert adverse effects on mitochondrial function, although the mechanisms underlying these e...
We established a new mouse strain using the Cre/loxP system, which enabled whole-body deletion of Hmgcr expression. These mice were crossed with Rosa26...
Lack of Hmgcr expression resulted in lethality, due to acute liver damage caused by rapid disruption of mitochondrial fatty acid β-oxidation and very high accumulation of long-chain (LC) acylcarnitine...
Our findings suggest that HMGCR is crucial for maintaining energy metabolism balance, and its activity is necessary for functional mitochondrial β-oxidation. Moreover, statin-induced adverse reactions...
As blood cholesterol increases, it accumulates in the intima of blood vessels, elevating the risk of atherosclerosis and coronary artery disease. Drugs that inhibit enzymes essential for cholesterol s...
Mitochondrial 3-hydroxymethylglutaryl-CoA synthase-2 (HMGCS2) is the main enzyme involved in ketogenesis. It is an essential enzyme for the catalysis of β-oxidation-derived-acetyl-CoA and acetoacetyl ...
Promiscuous enzymes have shown their synthetic abilities in generating various organic compounds with high selectively and efficiency under mild conditions. Therefore, the design and development of co...
Statins are cholesterol-lowering drugs that have exhibited potential as cancer therapeutic agents. However, as some cancer cells are resistant to statins, broadening an anticancer spectrum of statins ...
Two new fungal polyketides with unusual skeleton, collecapsins A and B (...
Vitamin K refers to a group of vitamins that play an important role in blood coagulation and regulation of bone and vascular metabolism. However, vitamin K...
Poly-3-hydroxybutyrate (P(3HB)), a member of the polyhydroxyalkanoate (PHA) family, is a biodegradable polyester with diverse industrial applications. NADPH-dependent acetoacetyl-CoA reductase (phaB) ...
Traumatic brain injuries (TBIs) are associated with high morbidity and mortality due to both the original insult as well as the destructive biological response that follows. Medical management aims to...
Malonyl-CoA reductase utilizes two equivalents of NADPH to catalyze the reduction of malonyl-CoA to 3-hydroxypropionic acid (3HP). This reaction is part of the carbon fixation pathway in the phototrop...